Evidence map›Paper›PMID 26209090›Full record

Trial reportWorld journal of urology2016

Vitamin D and prostate cancer prognosis: a Mendelian randomization study.

Olivia Trummer, Uwe Langsenlehner, Sabine Krenn-Pilko, Thomas R Pieber, Barbara Obermayer-Pietsch, Armin Gerger, Wilfried Renner, Tanja Langsenlehner

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in World journal of urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 5 pooled it
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 5 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Article
  9. Review
  10. Relative telomere length and prostate cancer mortality.Prostate cancer and prostatic diseases · 2018
    Article
  11. Article
  12. BCL2 genotypes and prostate cancer survival.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2017
    Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Olivia TrummerDivision of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Uwe LangsenlehnerDivision of Internal Medicine, GKK Outpatient Department, Graz, Austria.
Sabine Krenn-PilkoDepartment of Therapeutic Radiology and Oncology, Medical University of Graz, Graz, Austria.
Thomas R PieberDivision of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Barbara Obermayer-PietschDivision of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Armin GergerDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Wilfried RennerClinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036, Graz, Austria. wilfried.renner@medunigraz.at.
Tanja LangsenlehnerDepartment of Therapeutic Radiology and Oncology, Medical University of Graz, Graz, Austria.
Medical University of Graz · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDecreased vitamin D levels have been associated with prostate cancer, but it is unclear whether this association is causal. A functional single-nucleotide polymorphism (SNP) in the group-specific component (GC) gene (T > G, rs2282679) has been associated with 25-hydroxy (25-OH) vitamin D and 1.25 dihydroxy (1.25-OH2) vitamin D levels.

methodsTo examine the hypothesized inverse relationship between vitamin D status and prostate cancer, we studied the association between this SNP and prostate cancer outcome in the prospective PROCAGENE study comprising 702 prostate cancer patients with a median follow-up of 82 months.

resultsGC rs2282679 genotypes were not associated with biochemical recurrence [hazard ratios (HR) 0.91, 95 % confidence interval (CI) 0.73-1.12; p = 0.36], development of metastases (HR 1.20, 95 % CI 0.88-1.63; p = 0.25) or overall survival (HR 1.10; 95 % CI 0.84-1.43; p = 0.50).

conclusionsA causal role of vitamin D status, as reflected by GC rs2282679 genotype, in disease progression and mortality in prostate cancer patients is unlikely.

Indexed as

Polymorphism, Single NucleotideAgedAustriaBiomarkers, TumorDisease ProgressionDNA, NeoplasmGenotypeHumansMaleMendelian Randomization AnalysisPrognosisProspective StudiesProstatic NeoplasmsRisk FactorsSurvival RateVitamin D-Binding ProteinBiomarkers, TumorDNA, NeoplasmVitamin D-Binding ProteinGeneticsProstate cancerVitamin D

Identifiers

PMID26209090
OpenAlexW972450191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.